ReviewMolecules (Basel, Switzerland)2022
Phytochemical Compounds and Nanoparticles as Phytochemical Delivery Systems for Alzheimer's Disease Management.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Plant-mediated green nanoparticles: combining nanometal and biometabolite potential for Alzheimer's treatment.Biomedical engineering online · 2026Review
- Targeting oxidative stress and neurodegeneration: the role of Putranjiva roxburghii in Alzheimer's.Inflammopharmacology · 2026Review
- Structure-Based Design of New Series of Sulfonates with Potent and Specific BChE Inhibition and Anti-Inflammatory Effects.International journal of molecular sciences · 2026Article
- Diabetes and postoperative cognitive dysfunction and delirium in adults: mechanisms, biomarkers, and clinical management.Frontiers in endocrinology · 2026Review
- Synergistic Neuroprotection in Tauopathic Mice via Green-Synthesized Silver Nanoparticles Co-delivering Methylene Blue and Moringa oleifera.Molecular neurobiology · 2025Article
- Mechanisms Underlying the Cognitive Benefits ofPlants (Basel, Switzerland) · 2025Article
- Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders.World journal of experimental medicine · 2025Review
- Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Vesicular Carriers for Phytochemical Delivery: A Comprehensive Review of Techniques and Applications.Pharmaceutics · 2025Review
- Elucidating Anti-aging and Antioxidant Activity ofCombinatorial chemistry & high throughput screening · 2025Article
- Article
- Computational Frontiers in Aptamer-Based Nanomedicine for Precision Therapeutics: A Comprehensive Review.ACS omega · 2024Review
- The Therapeutic Potential ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Green synthesis of nanoparticles using medicinal plants as an eco-friendly and therapeutic potential approach for neurodegenerative diseases: a comprehensive review.Frontiers in neuroscience · 2024Review
- Role of phytocompounds as the potential anti-viral agent: an overview.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Nanopharmacology as a new approach to treat neuroinflammatory disorders.Translational neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease remains one of the most widespread neurodegenerative reasons for dementia worldwide and is associated with considerable mortality and morbidity. Therefore, it has been considered a priority for research. Indeed, several risk factors are involved in the complexity of the therapeutic ways of this pathology, including age, traumatic brain injury, genetics, exposure to aluminum, infections, diabetes, vascular diseases, hypertension, dyslipidemia, and obesity. The pathophysiology of Alzheimer's disease is mostly associated with hyperphosphorylated protein in the neuronal cytoplasm and extracellular plaques of the insoluble β-amyloid peptide. Therefore, the management of this pathology needs the screening of drugs targeting different pathological levels, such as acetylcholinesterase (AchE), amyloid
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.